However, given the complex role of therapy-induced senescence, including its potential to promote tumor progression via SASP, further preclinical and clinical studies are needed to assess whether combining ATM inhibitors with senolytic agents could enhance treatment outcomes while minimizing pro-tumorigenic side effects. Here, ATM is linked to neoplasm.